Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	9.74B -20.5%
Revenue (ttm)	1.50B +13.8%
Net Income	463.80M +30.1%
EPS	6.63 +30.1%
Shares Out	70.00M
PE Ratio	21.01
Forward PE	18.94
Dividend	4.00 (2.87%)
Ex-Dividend Date	Mar 2, 2026

Volume	3,058,531
Average Volume	241,434
Open	139.30
Previous Close	142.00
Day's Range	137.30 - 141.00
52-Week Range	125.00 - 183.80
Beta	0.50
RSI	56.77
Earnings Date	Feb 24, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,255
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2025, TADAWUL:4015's revenue was 1.50 billion, an increase of 13.82% compared to the previous year's 1.32 billion. Earnings were 463.80 million, an increase of 30.09%.